Valiant Laboratories shareholders approve all 18 AGM resolutions with high majority
- All 18 resolutions passed at Valiant Laboratories' 5th AGM held on September 28, 2026
- Santosh Vora re-appointed as MD for 5 years with 99.998% votes in favor
- Material related party transactions approved by public shareholders with >99.9% support
- Promoter group abstained from voting on RPTs but supported all other governance items
- Registered office shift within Maharashtra approved with 99.999% majority
*this image is generated using AI for illustrative purposes only.
Valiant Laboratories Limited concluded its 5th Annual General Meeting on September 28, 2026, with shareholders approving all 18 items of business. The scrutinizer’s report dated September 29, 2026, confirmed that every resolution passed with the requisite majority, including special resolutions for director re-appointments and ordinary resolutions for material related party transactions.
The meeting was conducted via Video Conferencing and Other Audio Visual Means, in compliance with SEBI (LODR) Regulations, 2015. A total of 38 members attended the meeting, comprising 8 from the promoter group and 30 public shareholders. Voting was conducted through remote e-voting provided by National Securities Depository Limited (NSDL).
Key Resolutions Passed
Shareholders voted on 18 items of business. The approval of material related party transactions involved entities such as Valiant Organics Limited, Aarti Pharmalabs Limited, and Alchemie Speciality Chemicals Private Limited. Notably, promoter group members abstained from voting on resolutions where they were interested parties, specifically items 4 through 8.
| Item | Resolution Type | Key Action | % For (Total) |
|---|---|---|---|
| Item 9 | Special Resolution | Re-appointment of Santosh Vora as Managing Director for 5 years | 99.998% |
| Item 10 | Special Resolution | Re-appointment of Sonal Vira as Independent Director for second term | 99.998% |
| Item 4-8 | Ordinary Resolution | Approval of material related party transactions with associated entities | 99.94% - 99.98% |
| Item 11 | Special Resolution | Revision in remuneration of Paresh Shah, Whole-Time Director and CFO | 99.998% |
| Item 13-17 | Special Resolution | Payment of commission to Non-Executive and Independent Directors | 99.61% |
| Item 18 | Special Resolution | Shifting of Registered Office within Maharashtra | 99.999% |
Management Commentary
During the meeting, Santosh Vora highlighted improved business performance in FY26, supported by stabilising market conditions in the paracetamol API sector. He noted the successful completion of a rights issue and the achievement of a debt-free balance sheet. The company also commenced commercial operations at its wholly owned subsidiary, Valiant Advanced Sciences Private Limited.
Vora outlined priorities for FY27, focusing on supporting subsidiary growth, strengthening export opportunities, and pursuing international quality certifications. He emphasized the company's focus on backward integration and operational excellence.
Board Composition Updates
The meeting addressed changes in board composition and remuneration. Sandeep Gupta, Non-Executive Director, retired by rotation and was re-appointed. Shantilal Vora, Non-Executive Director, received approval to continue his directorship upon attaining 75 years of age. Additionally, commission payments were approved for several non-executive and independent directors, including Mulesh Savla and Ashok Chheda.
What the Numbers Show
The voting pattern reveals a clear distinction between governance-related votes and those involving related party interests. For resolutions where promoters were not interested parties (e.g., Items 1, 2, 9, 10), promoter group participation was near-total (99.99% of their holding), driving the overall 'For' vote to approximately 99.99%. However, for Items 4 through 8 (Related Party Transactions), promoter group votes were zero due to conflict of interest restrictions. Consequently, these resolutions relied entirely on public non-institutional shareholders, who voted overwhelmingly in favor (99.94% to 99.97%). This indicates strong public shareholder confidence in the company's operational dealings with associated entities, despite the absence of promoter voting support.
Historical Stock Returns for Valiant Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.71% | -3.85% | +22.62% | +128.09% | +48.04% | -28.23% |
How will the newly approved material related party transactions with Valiant Organics and Aarti Pharmalabs specifically impact Valiant Laboratories' cost structure and margins in FY27?
What specific international quality certifications is Valiant Advanced Sciences targeting, and how might their achievement influence the company's export revenue potential?
Given the shift to a debt-free balance sheet, what capital allocation strategy will management prioritize for the subsidiary's growth versus shareholder returns?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
